NewAmsterdam Pharma Company N.V. (NAMSW)

Every figure this model derived for NAMSW, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 260,000 PaymentsToAcquireProductiveAssets 2026-06-30
cash 633,854,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 659,207,000 AssetsCurrent 2026-06-30
current liabilities 72,974,000 LiabilitiesCurrent 2026-06-30
equity 631,422,000 StockholdersEquity 2026-06-30
ocf -143,462,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 7,121,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30
sbc 65,416,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up NAMSW on one particular measure came for.

RatioValue
current ratio9.39
current ratio reported9.03
dilution pct25.52
fcf margin-2018.28
growth cv4.8
revenue growth-88.87
revenue growth per share-91.14
rule of 40-3521.08
sbc pct revenue918.64

What to be careful about

What this model itself distrusts about NAMSW's figures. Written by the derivation as it ran, not added afterwards.